Drug Index



Mechanism :

Nilotinib is a selective tyrosine kinase inhibitor that targets BCR-ABL kinase, c-KIT and platelet derived growth factor receptor (PDGFR).

Indication :

• Chronic myelogenous leukemia


• Acute lymphoblastic leukemia (ALL)

• Philadelphia chromosome-positive (Ph+)

• Gastrointestinal stromal tumor (GIST) (refractory)

Contraindications :

Hypersensitivity to nilotinib or any component of the formulation; persistent QTc >48 msec, Hypokalemia, hypomagnesemia, or long QT syndrome.

Dosing :

≥1 year: Oral: 230 mg/m2 twice daily (rounded to the nearest 50 mg dose); Maximum: 400 mg (as a single dose) twice daily.

Adverse Effect :

Rash, headache, nausea, pruritus, fatigue, fever, diarrhea, constipation, vomiting, arthralgia, cough, extremity pain, asthenia, muscle spasms, myalgia, abdominal pain, bone pain, back pain, dyspnea, nasopharyngitis, peripheral edema, dizziness, QTc prolongation, hyperglycemia, hyperkalemia, hypomagnesemia, neutropenia, pancytopenia, Hepatitis B virus reactivation, Thrombotic microangiopathy.

Interaction :

Antacids: May decrease the serum concentration of Nilotinib.
Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CYP3A4 Inducers: May decrease the serum concentration of Nilotinib.
CYP3A4 Inhibitors: May increase the serum concentration of Nilotinib.
QT-prolonging Agents: May enhance the QTc-prolonging effect of Nilotinib.
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of live vaccines.

01/30/2020 06:11:58 Nilotinib
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0